公开(公告)号：US20200093801A1

公开(公告)日：2020-03-26

申请号：US16495754

申请日：2018-03-26

Applicant: Novartis AG

Inventor： Derya SHIMSHEK

IPC: A61K31/426 ,  A61K31/4439 ,  A61P25/28

Abstract: The present invention relates to methods of treating multiple sclerosis, amyotrophic lateral sclerosis (ALS) or Alzheimer's disease in a subject in need of treatment thereof by administering an effective amount of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20250136685A1

公开(公告)日：2025-05-01

申请号：US18999104

申请日：2024-12-23

Applicant: Novartis AG

Inventor： Verena BRAND ,  Dominik FEUERBACH ,  Fabrizio GASPARINI ,  Nathalie GEORGE ,  Eveline SCHAADT ,  Derya SHIMSHEK ,  Honnappa SRINIVAS ,  Markus WALDHUBER ,  Rainer WILCKEN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61P25/28 ,  C12N7/00 ,  C12N15/70

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US20180125853A1

公开(公告)日：2018-05-10

申请号：US15730175

申请日：2017-10-11

Applicant: Novartis AG

Inventor： Cristina LOPEZ-LOPEZ ,  Ulf NEUMANN ,  Derya SHIMSHEK

IPC: A61K31/5377 ,  A61P9/10

Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.

公开(公告)号：US20230167174A1

公开(公告)日：2023-06-01

申请号：US17934795

申请日：2022-09-23

Applicant: Novartis AG

Inventor： Verena BRAND ,  Dominik FEUERBACH ,  Fabrizio GASPARINI ,  Nathalie GEORGE ,  Eveline SCHAADT ,  Derya SHIMSHEK ,  Honnappa SRINIVAS ,  Markus WALDHUBER ,  Rainer WILCKEN

IPC: C07K16/28 ,  A61P25/28 ,  A61K39/395 ,  C12N7/00 ,  C12N15/70

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61P25/28 ,  C12N7/00 ,  C12N15/70 ,  A61K2039/505

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.